GRI Bio, Inc. (GRI): Nasdaq/NYSE listing notice — GRI Bio conditionally regains Nasdaq equity compliance after prior deficiency

GRI Bio, Inc.

Nasdaq Staff notified GRI Bio on Jan 15, 2026 that it conditionally regained compliance with the Stockholders' Equity Requirement (Nasdaq Listing Rule 5550(b)(1)).
The requirement mandates at least $2.5 million in stockholders' equity for companies with market value under $35 million and annual net income below $500,000.
Non-compliance was previously reported in a Dec 2, 2025 8-K based on the Sept 30, 2025 10-Q.
If future Exchange Act reports fail to show compliance, common stock may again face delisting.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

GRI Bio, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

January 15, 2026, GRI Bio, Inc. (the “Company”) was formally notified by the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Staff has determined that the Company has conditionally regained compliance with the equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) which requires that companies listed on the Nasdaq Capital Market with a market value of less than $35 million and annual net income of less than $500,000 maintain stockholders’ equity of at least $2.5 million (the “Stockholders’ Equity Requirement”). As previously reported on the

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

GRI Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001824293-26-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.